CLINICAL TRIAL: PHOSPHODIESTE RASE-5 INHIBITION IN DIASTOLIC HEART FAILURE (RELA

临床试验：磷酸二酯酶 5 抑制舒张性心力衰竭 (RELA

• 批准号: 7952127
• 负责人: MARTIN M LEWINTER
• 金额: $ 0.28万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952127
• 关键词: Chronic; Clinical; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diastolic heart failure; Double-Blind Method; EFRAC; Exercise; Funding; Grant; Heart failure; Institution; Measures; Patients; Performance; Placebos; RELA gene; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; improved; inhibitor/antagonist; placebo controlled study; sildenafil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a double-blind, placebo controlled study testing the hypothesis that chronic PDE-5 inhibition (sildenafil 80 mg tid for 24 weeks) improves exercise capacity and clinical status in patients with heart failure and normal ejection fraction. This study also measures the effect of this therapy on key pathophysiological parameters which are postulated to impact clinical status and exercise performance in diastolic heart failure. 120 patients will be studied. Approximately 10 here at FAHC. The primary endpoint is change in exercise capacity as assessed by peak VO2 after 24 weeks of double-blinded treatment PDE-5 inhibitor or placebo.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项双盲，安慰剂对照研究，检验了慢性PDE-5抑制作用（西地那非80 mg TID 24周）可提高心力衰竭和正常射血分数患者的运动能力和临床状况。 这项研究还衡量了该疗法对关键病理生理参数的影响，这些参数被认为会影响舒张期心力衰竭的临床状况和运动表现。 将研究120名患者。 在FAHC大约有10个。 主要终点是在双盲治疗PDE-5抑制剂或安慰剂24周后通过峰值VO2评估的运动能力变化。